Digital Science empowers biopharma R&D teams with trusted intelligence across the entire research lifecycle — from emerging science and literature discovery to clinical development and IP analysis. Our platforms transform fragmented research, clinical, and patent data into actionable insights that accelerate discovery, repurposing, and development.
Don’t miss our keynote “AI and the Perpetual Research Cycle: Accelerating Drug Discovery through Enhanced Literature Analysis” by Mark Hahnel, Vice President of Open Research, Digital Science, at 08:30 – 09:00AM.
Abstract:
This talk explores the transformative impact of Artificial Intelligence (AI) on the research lifecycle, with a focus on its application in accelerating drug discovery. It introduces the concept of the “Perpetual Research Cycle,” where AI facilitates the continuous flow from data to papers and knowledge, driving innovation in scientific research. The discussion will highlight how AI tools enhance critical stages of this cycle, particularly in literature analysis and review, which are fundamental to drug discovery.
The presentation will showcase specific AI-driven solutions that streamline systematic literature reviews, enable continuous monitoring of relevant publications, and enhance the precision and efficiency of data extraction from scientific literature. By automating and accelerating these processes, AI empowers researchers to derive deeper insights from vast amounts of scientific data, ultimately leading to faster and more effective drug discovery. The talk will also address key considerations for responsible AI implementation in research, ensuring trust, accuracy, and reliability in the quest for new therapies.
Meet our speaker
Mark Hahnel
Mark Hahnel is the VP of Open Research at Digital Science. He is the founder of Figshare, which he created whilst completing his PhD in stem cell biology at Imperial College London. He is passionate about open science and the potential it has to revolutionize the research community. Mark sits on the board of DataCite and the advisory board for Directory of Open Access Journals (DOAJ) and re3data.
